Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 13 Dec 2016
At a glance
- Drugs Dasatinib (Primary) ; Zoledronic acid (Primary)
- Indications Advanced breast cancer; Bone metastases
- Focus Adverse reactions
- 08 Dec 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
- 10 May 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 08 Dec 2015 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017, according to ClinicalTrials.gov record.